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Abstract  
A novel series of dihydronaphtalene, tetrahydronaphtalene and naphtalene derivatives as restricted-analogues of isoCA-
4 were designed, synthesized and evaluated for their anticancer properties. High cell growth inhibition against four 
tumor cell lines was observed at a nanomolar level with dihydronaphtalenes 1d,e and 1h, tetrahydronaphtalene 2c and 
naphtalene 3c. Structure activity relationships are also considered. These compounds exhibited a significant inhibitory 
activity toward tubulin polymerization (IC50 = 2-3 M), comparable to that of isoCA-4. The effect of the lead 
compounds 1e and 2c on the cancer cells tested was associated with cell cycle arrest in the G2/M phase. Docking studies 
reveal that these compounds showed a binding mode similar to those observed with their non-constraint isoCA-4 and 
isoerianin congeners. 
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1. Introduction 
Microtubules found in cytoskeleton of almost all eukaryotic cell types are hollow tubes formed by self-assembly of  
and  tubulin heterodimers. They are directly involved in a variety of cellular functions, such as cell movement, 
transport of organelles inside the cell, maintenance of cell shape as well as mitosis and cell replication. Consequently, 
perturbation of tubulin assembly/disassembly is a popular target for new chemotherapeutic agents.[1,2] The vinca 
alkaloids, typified by vinblastine and vincristine which inhibit microtubules assembly[3] as well as the taxanes, such as 
paclitaxel and docetaxel which promoted microtubules polymerization and inhibits microtubules depolymerization,[4,5] 
are the mostly used antimicrotubules agents introduced in clinical oncology.[6] However, despite their potent antitumor 
activities, these drugs have undesirable side effects[7,8] and are subject to multidrug resistance.[9,10] These last 
decades, there has been a strong enthusiasm for discovering tubulin polymerization inhibitors of small size, easy 
synthesis and low side effects. Combretastatin A-4 (CA-4, Figure 1), a cis-stilbene extracted from the South African 
willow Combretum caffrum[11,12] is arguably the most studied substance that displays a nanomolar level of 
cytotoxicity against a variety of human cancer cells, including multidrug resistant cell lines.[13,14] CA-4 binds at or 
near colchicine binding site of -tubulin and strongly interferes with the assembly of tubulin, leading to cell death.[15] 
It also exerts highly selective effects in proliferating endothelial cells and, as a consequence, demonstrates strong 
suppressive activity on tumor blood flow leading to tumor necrosis.[16] Two derivatives are currently in clinical trials: 
CA-4 disodium phosphate CA-4P,[17,18] a water soluble prodrug of CA-4 and the aminocombretastatin prodrug AVE-
8062 (3).[19,20] To date, CA-4P[21] either as a single agent or in combination therapy is undergoing several advanced 
clinical trials worldwide for the treatment of age-related macular degeneration or anaplastic thyroid cancer. 
Despite its remarkable anticancer activity, the main disadvantage of CA-4 is the ready isomerization of the Z-double 
bond to its inactive trans-form during storage, administration[22] and metabolism.[23] In an ongoing project aimed at 
developing novel tubulin assembly inhibitors,[24,25,26,27,28,29] we recently discovered isocombretastatin A-4 
(isoCA-4), a structural isomer of the natural product, which holds biological activities comparable to that of CA-4.[30] 
This substance having a 1,1-diarylethylene scaffold is easy to synthesize[31,32,33] at a multi grams scale without the 
need to control the olefin geometry and then definitively solving the Z double bond isomerization problem.[34]  
<Figure 1> 
By structural modifications on the B-ring, we have also identified other promising antiproliferative agents such as 
isoNH2CA-4 and isoFCA-4 (Figure 1).[35,36] We also demonstrated that the bioisosteric replacement of the (Z)-1,2-
ethylene by the 1,1-ethylene could be apply successfully to natural combretastatins CA-2, CA-3 and CA-5.[30] On the 
basis of these bioisosteric considerations, we also showed that isoerianin derivatives having a 1,1-diarylethane scaffold 
were as active as the natural product erianin.[37] A set of molecular docking calculations was performed with isoCA-4 
as well as isoerianin which showed a binding pose similar to those observed with CA-4 and the co-crystallized DAMA-
colchicine in the colchicine binding site.[38] In addition, the dihedral angles between the planes of the two A/B-
aromatic nucleus in isoCA-4 and isoerianin (68° and 77°, respectively)[30,37] were found to be close to that of CA-4 
(53°).[39] From all of these considerations, we are planning to rationalize the synthesis of three new series of rigid 
analogues of isoCA-4 and isoerianin namely, 4-aryldihydronaphtalenes 1 (e.g.; dihedral angle = 69° for 1e), 4-
aryltetrahydronaphtalenes 2 (e.g.; dihedral angle = 79° for 2c) and 1-arylnaphtalenes 3 (e.g.; dihedral angle = 70° for 
3d) with reduced mobility of the B-ring. We hypothesized that constrained analogues 1-3 with dihedral angles close to 
those of isoCA-4 and isoerianin would be as active as their non restricted congeners. In this paper we would like to 
describe the synthesis and evaluation of compounds 1-3 in terms of inhibition of tubulin assembly along with 
cytotoxicity studies against various cancer cell lines. 
<Scheme 1> 
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Reagents and conditions: (i) pTsNHNH2 (1.2 equiv), PTSA (0.2 equiv), MgSO4 (1 equiv), EtOH, 50 °C. (ii) ArI (1.1 
equiv), Pd2dba3 (10 mol%), XPhos (20 mol%), LiOtBu (2.2 equiv), dioxane 90 °C in a sealed tube. (iii) 3,4,5-
trimethoxyiodobenzene (1.1 equiv), Pd2dba3 (10 mol%), XPhos (20 mol%), LiOtBu (2.2 equiv), dioxane 90 °C in a 
sealed tube. (iv) NaN3 (2 equiv), CuI 10 mol%, DMEDA (15 mol%), sodium ascorbate (5 mol%), DMSO/H2O: 5/1, 60 
°C. (v) KOH (5 equiv), Pd2dba3 (10 mol%), tBuXPhos (20 mol%), dioxane/H2O: 1/1, 90 °C in a sealed tube. (vi) 
Alkyne (1.2 equiv), PdCl2(PPh3)2 (5 mol%), PPh3 (10 mol%), CuI (10 mol%), Et2NH (2 equiv), DMF, MWI, 120 °C. 
(vii) Methyl acrylate (10 equiv), PEPPSI (5 mol%), K2CO3 (2 equiv), NMP 140 °C in a sealed tube. (viii) H2, Pd/C in 
MeOH. (ix) DDQ (1.2 equiv), CH2Cl2, 20 °C. 
2. Results and discussion 
2.1. Chemistry. 
Scheme 1 outlines the convergent synthetic routes followed for the synthesis of the novel restricted analogues 1-3. The 
projected incorporation of a variety of substituents at the C3’ position of the B-ring 
bond, which can further be engaged into diverse coupling reactions. Thus, the preparation of the pivotal brominated 
precursors 1a and 1b was achieved from 5-bromo-6-methoxytetralone 4b[40] which was heated in EtOH at 50 °C with 
TsNHNH2 in the presence of PTSA. The resulting N-tosylhydrazone 5b was next coupled with aryl iodides under 
palladium catalysis[30,41,42] to afford the key intermediates 1a,b. By securing the required skeleton for the 
dihydronaphtalene analogues, the stage was ready for the installation of various functionalities in place of the bromine 
atom. The C(sp2 2 bond of 1d and 1i was formed from 1a and 1b, respectively, using sodium azide as the amino 
source[43,44] in the presence of a catalytic amount of CuI. Treating 1a,b with KOH in the presence of Pd2dba3, 
tBuXPhos in a mixture dioxane/H2O: 1/1 at 90 °C[45] delivered in good yields the C3’-hydroxy substituted analogues 
1e (63%) and 1h (62%). For the introduction of alkyne substituents on the B-aromatic ring,[36] we examined the 
Sonogashira-Linstrumelle reaction[46] of 1a with propargylic and homopropargylic alcohols. The coupling reaction of 
these alcohols with 1a proceeded in the presence of PdCl2(PPh3)2 and CuI catalysts under microwave irradiation (MWI) 
at 120 °C to give the corresponding alkynes 1f,g in good yields. Similarly, 1a underwent Heck coupling with methyl 
acrylate using [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(II) dichloride (PEPPSI) as 
the catalyst in NMP at 140 °C to afford the corresponding 3’methyl (E)-cinnamate 1j in an unoptimized 35% yield. 
Having achieved the preparation of dihydronaphtalenes 1, we next focused our attention on their catalytic reduction to 
give restricted isoerianin analogues 2. Thus, 4-aryltetrahydronaphtalenes 2a-e were obtained in acceptable yields using 
H2 in the presence of Pd/C in MeOH. Finally, aromatization of compound 1a into naphtalene derivative 3a was 
attempted using a variety of oxidizing species, including Pd/C, SeO2, o-chloranil, p-chloranil, and SO3-pyridine 
complex. However, the oxidation reactions were unsuccessful and gave 3a in very poor yields (<10 %). After several 
trials, we found that the oxidation of 1a with DDQ in CH2Cl2 afforded the desired naphtalene 3a but in a moderate 33% 
yield. Introduction of various substituents on 3a was next achieved in a similar manner as described above for 1d-j from 
1a,b. Using a similar route for the synthesis of 1d, dihydronaphtalene 1l bearing a NH2 substituent at the C-7 position 
was prepared from 7-bromo-6-methoxytetralone 4c[47] for structure-activity relation study (Scheme 2). 
<Scheme 2> 
Reagents and conditions: (i) pTsNHNH2 (1.2 equiv), PTSA (0.2 equiv), MgSO4 (1 equiv), EtOH, 50 °C. (ii) 3,4,5-
trimethoxyiodobenzene (1.1 equiv), Pd2dba3 (10 mol%), XPhos (20 mol%), LiOtBu (2.2 equiv), dioxane 90 °C in a 
sealed tube. (iii) NaN3 (2 equiv), CuI (10 mol%), DMEDA (15 mol%), sodium ascorbate (5 mol%), DMSO/H2O: 5/1, 
60 °C.  
<Table 1> 
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2.2. Biological results. 
In vitro antiproliferative activity of the synthesized naphthalene derivatives 1-3 was first determined against the human 
colon carcinoma cell line (HCT116) using CA-4[48] and isoCA-4[30] and isoerianin[37] as reference compounds. The 
results of this study are summarized in Table 1. On the exception of the amino derivative 3c (GI50 = 55 nM), naphtalene 
compounds 3 displayed only modest antiproliferative activity, which was affected with halogen (Br, 3a), alkynol (3e, 
3f), alkene (3g) and alkyl (3h) substituents at the C5 position. In contrast, dihydronaphtalenes 1 were significantly more 
active than their aromatic congeners. In particular, dihydronaphtalenes 1d and 1e[49] bearing the greatest resemblance 
to isoNH2CA-4 and isoCA-4, respectively, displayed a high antiproliferative activity at a nanomolar level (GI50 = 7 and 
85 nM). By comparison with 1d, the introduction of an amino substituent at the C7 position failed to improve the 
cytotoxic activity profile of 1l. One note that compounds 1h and 1i bearing two methoxy groups on the A-ring retained 
an important cytotoxicity in comparison with 1e and 1d, respectively. Nevertheless, on the contrary with previous 
reports,[36] decreased cytotoxic activity was observed with dihydronaphtalenes 1f,g and 1j bearing alkynol or alkene 
substituents at the C5 position.  
The reduction of 1 into tetrahydronaphtalenes 2 as restricted isoerianin analogues led to compounds that displayed 
similar cytotoxic activities in comparison with isoerianin (GI50 = 28 nM) and with their dihydronaphtalenes precursors. 
For example, 2c with a GI50 value of 20 nM was slightly more active than restricted isoCA-4 1e (85 nM), while the 
amino derivative 2b was about ten fold less active than its dihydronaphtalene analogue 1d. These results indicated that 
rigidifying isoCA-4 or isoerianin with the dihydro- or tetrahydronaphtalene system did not alter the reported SAR. 
These preliminary in vitro cytotoxic results prompted us to evaluate the most promising molecules in these series 
against other human cancer cell lines. The GI50 values of selected compounds obtained with K562 (chronic mylogenous 
leukemia), H1299 (non-small lung human carcinoma) and MDA-MB231 (human breast) cell lines are summarized in 
Table 2. 
<Table 2> 
Results from the cytotoxicity study provide evidence that dihydronaphtalenes 1d, 1e, 1h, 1i which retained a high level 
of cytotoxicity against HCT116 (Table 1) cells were also strongly cytotoxic against H1299, MDA-MB231 and K562 
cancer cell lines. Similarly, tetrahydronaphtalenes 2a-c as well as naphtalene derivative 3c displayed an equivalent level 
of cytotoxicity against the three tested cancer cells (30< GI50 <150 nM).  
To confirm that the antiproliferative activities of these compounds, like those in the isoCA-4[30] and isoerianin 
series,[37] were related to an interaction with the microtubule system, these selected compounds were evaluated for 
their inhibitory effects on tubulin assembly (Table 2). Except for dihydronaphtalenes 2a and 2b, the results 
demonstrated that the drug cytotoxicity correlated with the inhibition of tubulin polymerization. For instance, 
dihydronaphatalenes 1d,e, 1h,i, tetrahydronaphtalene 2c and naphtalene 3c were found to be as active as isoCA-4 and 
CA-4, displaying an IC50 at a micromolar level. One note that naphtol derivative 3d, bearing the greatest ressemblance 
to isoCA-4, showed a reduced antitubulin activity (IC50 = 6.9 M) which was consistent with the results of the growth 
inhibitory effect (310 nM< GI50<500 nM). 
Because molecules exhibiting effects on tubulin polymerization causes the alteration of cell cycle parameters, the effect 
of tetrahydronaphtalene 2c, dihydronaphtalene 1e, and naphtalene 3d on MDA-MB231, K562, HCT116 and H1299 
cellular cycle was investigated. The fluorescent propidium iodide intercalates with the DNA and hence, the amount of 
fluorescence measured per cell is proportional to the DNA content. Cells were harvested after 24 h and analyzed for 
DNA content by flow cytometry. Table 3 shows that a significant increased in G2/M peak is observed after treatment of 
the four cell lines with tetrahydronaphtalene 2c at a low concentration (5.10-9 M). Similarly, dihydronaphtalene 1e as 
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well as naphtalene derivative 3d arrest the majority of cells in the G2/M phase of the cell cycle but at concentrations 
smootly superiors (10-8 M and 5.10-7 M, respectively).  
<Table 3> 
2.3. Docking study. 
These results clearly demonstrated that tubulin is the target of these compounds; however, the specific binding site on 
tubulin was not investigated, for example, by use of a radiolabeled colchicine displacement assay. Nevertheless, a set 
molecular docking calculations was performed with 5-OH naphtalene derivatives to investigate the possible binding 
mode of 2c, 1e and 3d which were docked in the colchicine binding site of tubulin. For this purpose, the X-ray structure 
of tubulin DAMA-colchicine complex (Code PDB: 1sa0)[38] was used. Figure 2 illustrates from one hand, the docking-
derived superimposition of 2c and 1e, with isoCA-4 (blue), and on the other hand, the superimposition of 3d with 
isoerianin (green). As expected, these compounds showed a binding pose similar to the one observed with the reference 
compounds isoCA-4 and isoerianin with the trimethoxyphenyl ring placed in proximity of Cys241 and the OH 
substituent of the B-ring (naphtalene, dihydro- and tetrahydronaphtalene) which forms a hydrogen-bond with Val181. 
These binding parallels and the dihedral angles values of 2c (79°), 1e (69°) and 3d (70°) probably rationalise the 
potency observed for these drugs in their tubulin effects which are seen to be close to that reported for isoCA-4 
(dihedral angle = 68°)[30] and isoerianin (dihedral angle = 77°).[37] 
<Figure 2> 
3. Conclusion 
We designed and synthesized by a convergent strategy, three new classes of synthetic inhibitors of tubulin 
polymerization based on the molecular skeleton of dihydronaphtalenes 1, tetrahydronaphtalenes 2 and naphtalenes 3. 
These restricted analogues of isoCA-4 and isoerianin were evaluated for their antiproliferative activity against various 
human cancer cell lines. The lead compounds, dihydronaphtalenes 1e-h, tetrahydronaphtalenes 2b,c and to a lesser 
extent naphtalene 3c displayed potent cytotoxicities with GI50 ranging from 15 to 110 nM. In these three series, six of 
the most cytotoxic compounds were evaluated for effects on tubulin polymerization and the IC50 values in a nearly 
range of 3 M are comparable to that of isoCA-4. The three most potent inhibitors of tubulin assembly having the 
greatest ressemblance to isoCA-4, 2c, 1e and 3d induced a prevalent block of cells in G2/M phase of the cell cycle at 
nanomolar concentrations. In addition, docking studies revealed that these compounds adopted an orientation similar to 
that of isoCA-4 and isoerianin in the colchicine binding-site. Biological results obtained in this study demonstrate that 
structural restrictions at this portion of isoCA-4 offers various permises for the design of novel heterocycle-containing 
restricted isoCA-4 derivatives. Synthesis and biological evaluation of such compounds are under investigation in our 
laboratory and will be reported in due course. 
4. Experimental 
4.1 General considerations 
Triethylamine was distilled from potassium hydroxide under argon prior to use. The compounds were all identified by 
usual physical methods, i.e. 1H-NMR, 13C-NMR, IR, MS and elemental analysis. 1H and 13C NMR spectra were 
measured in CDCl3 with a Bruker Avance 300. 1H chemical shifts are reported in ppm from an internal standard TMS 
or of residual chloroform (7.27 ppm). The following abbreviations are used: m (multiplet), s (singlet), d (doublet), br s 
(broad singlet), t (triplet). 13C chemical shifts are reported in ppm from the central peak of CDCl3 (77.14). IR spectra 
were measured on a Bruker Vector 22 spectrophotometer (neat, cm-1). Elemental analyses were performed with a 
Perkin-Elmer 240 analyser. Mass spectra were obtained with a LCT Micromass spectrometer. Analytical TLC was 
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performed on Merck precoated silica gel 60F plates. Merck silica gel 60 (230-400 mesh) was used for column 
chromatography.  
4.2. Bromination of 6-methoxytetralone was achieved according to literature to give 4b and 4c.[40] 
4.2.1 5-Bromo-6-methoxytetralone (4b) 
Yield: 49 %. TLC: Rf 0.52 (cyclohexane/EtOAc: 9/1). IR (neat) νmax/ cm-1: 3904, 3232, 1664, 1568, 1458, 1415, 1352, 
1327, 1280, 1232, 1188, 904, 826, 776, 729, 638. 1H NMR (300 MHz, CDCl3) δ ppm 8.06 (d, J = 8.7 Hz, 1H), 6.88 (d, 
J = 8.7 Hz, 1H), 3.97 (s, 3H), 3.03 (t, J = 6.2 Hz, 2H), 2.66 – 2.54 (m, 2H), 2.14 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 
196.9, 159.8, 145.6, 128.5, 127.7, 113.1, 109.7, 56.6, 38.1, 30.6, 22.6. MS (APCI, m/z) 255.1 ([M + H]+, 79Br), 257.0 
([M + H]+, 81Br). 
4.2.2 7-Bromo-6-methoxytetralone (4c) 
Yield: 7 %. Rf 0.45 (cyclohexane/ EtOAc: 9/1). IR (neat) νmax/ cm-1: 3628, 3238, 1668, 1568, 1459, 1413, 1352, 1327, 
1283, 1260, 1232, 1188, 902, 778, 733, 640. 1H NMR (300 MHz, CDCl3) δ ppm 8.21 (s, 1H), 6.69 (s, 1H), 3.94 (s, 3H), 
2.91 (t, J = 6.0 Hz, 2H), 2.75 – 2.41 (m, 2H), 2.12 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 196.0, 159.6, 159.4, 151.4, 
145.9, 132.6, 110.8, 56.4, 38.5, 29.9, 23.2. MS (APCI, m/z) 255.0 ([M + H]+, 79Br), 257.0 ([M + H]+, 81Br). 
4.3. General procedure for the formation of N-tosylhydrazones. 
To a solution of tetralone 4b,c (1 mmol), PTSA (0.2 mmol) and MgSO4 (1 mmol) in ethanol (20 mL) was added 4-
methylbenzenesulfonohydrazide (1.2 mmol). The resulting mixture was stirred under reflux for 2 h. After cooling at 
room temperature, the medium was diluted with EtOAc and filtered over a pad of Celite. The solvent was next removed 
and the residue was purified by crystallization in ethanol to afford 5b,c. 
4.3.1. N’-(5-Bromo-6-methoxy-3.4-dihydronaphtalen-1(2H)-ylidene)-4-methylbenzenesulfonohydrazide (5b) 
Yield: 100 %. M.p. 212.1°C Rf 0.5 (cyclohexane/EtOAc: 7/3). IR (neat) νmax/ cm-1: 2249, 1054, 1025, 1006, 821, 758, 
623. 1H NMR (300 MHz, DMSO) δ ppm 10.51-10.03 (br s, 1H), 7.85 – 7.73 (m, 3H), 7.40 (d, J = 8.1 Hz, 2H), 7.01 (d, 
J = 8.9 Hz, 1H), 3.85 (s, 3H), 2.75 (t, J = 6.0 Hz, 2H), 2.52 - 2.47 (m, 2H), 2.37 (s, 3H), 1.77 (m, 2H). 13C NMR (75 
MHz, DMSO) δ 156.21, 152.15, 143.14, 140.06, 136.50, 129.39 (2C), 127.61 (2C), 126.37, 124.76, 112.31, 110.58, 
56.39, 29.29, 25.12, 21.03, 20.86.  
4.3.2. N’-(7-Bromo-6-methoxy-3.4-dihydronaphtalen-1(2H)-ylidene)-4-methylbenzenesulfonohydrazide (5c) 
Yield: 98 %. M.p. 236°C Rf 0.5 (cyclohexane/ EtOAc: 7/3). IR (neat) νmax/ cm-1: 2249, 1054, 1025, 1016, 992, 821, 
701, 654. 1H NMR (300 MHz, DMSO) δ ppm 10.39 (br s, 1H), 7.92 – 7.70 (m, 3H), 7.42 (d, J = 7.8 Hz, 2H), 6.91 (s, 
1H), 3.84 (s, 3H), 3.35 – 3.30 (m, 2H), 2.76 – 2.59 (m, 2H), 2.38 (s, 3H), 1.85 – 1.65 (m, 2H). 13C NMR (75 MHz, 
DMSO) δ 156.3, 152.1, 143.8, 141.8, 136.7, 129.9 (2C), 128.8, 127.9 (2C), 126.0, 112.5, 109.3, 56.8, 29.1, 25.9, 21.5, 
21.4. 
4.4. General procedure for the coupling of N-tosylhydrazones with aryl iodides. 
To a dioxane (2 mL) solution of N-tosylhydrazone (0.24 mmol), tBuOLi (0.53 mmol), Pd2dba3 (0.02 mmol), and XPhos 
(0.04 mmol) was added the required aryl iodide (0.24 mmol). The mixture was stirred at 90 °C for 5 h. CH2Cl2 (5 mL) 
was then added to the cooled mixture which was filtered over a pad of Celite. After concentration, the residue was 
purified by silica gel chromatography to yield 1a-c, 1k. 
4.4.1. 8-Bromo-7-methoxy-4-(3,4,5-trimethoxyphenyl)-1,2-dihydronaphtalene (1a) 
Yield: 76 %. Rf 0.4 (cyclohexane/EtOAc: 7/3). IR (neat) νmax/ cm-1: 2931, 1591, 1421, 1331, 1267, 1204, 1154, 1062, 
994, 906, 857, 729, 648. 1H NMR (300 MHz, CDCl3) δ 6.90 (d, J = 8.5 Hz, 1H), 6.60 (d, J = 8.5 Hz, 1H), 6.45 (s, 2H), 
5.91 (t, J = 4.6 Hz, 1H), 3.81 (s, 6H), 3.77 (s, 6H), 2.96 (t, J = 7.9 Hz, 2H), 2.33 (dt, J = 4.8 Hz, J = 7.9 Hz, 2H). 13C 
NMR (75 MHz, CDCl3) δ 154.9, 153.0 (2C), 139.2, 138.2, 137.3, 136.4, 129.8, 125.4, 125.4, 113.6, 108.8, 105.9 (2C), 
60.9, 56.3, 56.1 (2C), 28.1, 23.0. MS (APCI, m/z) 405.7 ([M + H]+, 79Br), 407.2 ([M + H]+, 81Br). Anal. Calcd for 
C20H21BrO4: C 59.27, H 5.22, found C 59.10, H 5.09. 
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4.4.2. 8-Bromo-4-(3,5-dimethoxyphenyl)-7-methoxy-1,2-dihydronaphtalene (1b) 
Yield: 84 %. Rf 0.47 (cyclohexane/EtOAc: 7/3). IR (neat) νmax/ cm-1: 2931, 1591, 1421, 1267, 1204, 1154, 1062, 906, 
729, 648. 1H NMR (300 MHz, CDCl3) δ 6.98 (d, J = 8.5 Hz, 1H), 6.66 (d, J = 8.5 Hz, 1H), 6.49 – 6.40 (m, 3H), 6.00 (t, 
J = 4.7 Hz, 1H), 3.88 (s, 3H), 3.79 (s, 6H), 3.12 – 2.94 (m, 2H), 2.49 – 2.28 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 
160.62 (2C), 154.9, 142.8, 139.2, 138.1, 129.7, 125.5, 115.8, 113.6, 108.8, 106.9 (2C), 99.4, 56.3, 55.3 (2C), 28.1, 23.0. 
MS (APCI, m/z) 375.15 ([M + H]+, 79Br), 377.36 ([M + H]+, 81Br). Anal. Calcd for C19H19BrO3: C 60.81, H 5.10, found 
C 60.54, H 4.99. 
4.4.3. 7-Methoxy-4-(3,4,5-trimethoxyphenyl)-1,2-dihydronaphtalene (1c) 
Yield: 75%. Rf 0.57 (cyclohexane/EtOAc: 8/2). IR (neat) νmax/ cm-1: 2934, 2834, 1589, 1496, 1453, 1421, 1358, 1301, 
1278, 1249, 1203, 1150, 1117, 1062, 1039, 1000. 1H NMR (300 MHz, CDCl3) δ 6.93 (d, J = 8.5 Hz, 1H), 6.71 (d, J = 
2.6 Hz, 1H), 6.59 (dd, J = 2.6 Hz, J = 8.5 Hz, 1H), 6.49 (s, 2H), 5.89 (t, J = 4.7 Hz, 1H), 3.82 (s, 3H), 3.77 (s, 6H), 3.74 
(s, 3H), 2.76 (t, J = 7.9 Hz, 2H), 2.31 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 158.6, 152.9, 139.5, 138.6 (2C), 137.1, 
136.7, 128.1, 126.7, 124.8, 113.8, 110.8, 105.7 (2C), 60.9, 56.1 (2C), 55.3, 28.8, 23.4. MS (APCI, m/z) 327.9 [M + 
H]+. Anal. Calcd for C20H22O4: C 73.60, H 6.79, found C 73.54, H 6.69. 
4.4.4. 6-Bromo-7-methoxy-4-(3,4,5-trimethoxyphenyl)-1,2-dihydronaphtalene (1k) 
Yield: 78 %. Rf 0.47 (cyclohexane/EtOAc: 8/2). IR (neat) νmax/ cm-1: 2934, 2833, 1580, 1505, 1490, 1465, 1449, 1411, 
1360, 1337, 1255, 1237, 1166, 1126, 1018, 1003, 907, 730, 646. 1H NMR (300 MHz, CDCl3) δ 6.78 (s, 1H), 6.66 (s, 
1H), 6.53 (s, 2H), 6.00 (t, J = 4.6 Hz, 1H), 3.92 (s, 3H), 3.90 (s, 3H), 3.85 (s, 6H), 2.81 (t, J = 7.8 Hz, 2H), 2.39 (m, 
2H). 13C NMR (75 MHz, CDCl3) δ 154.5, 153.1 (2C), 138.7, 137.7, 137.3, 135.9, 130.1, 129.3, 125.7, 111.7, 108.6, 
105.6 (2C), 60.9, 56.3, 56.1 (2C), 28.5, 23.2. MS (APCI, m/z) 405,1 ([M+H]+, 79Br ), 407.4 ([M+H]+, 81Br).. Anal. Calcd 
for C20H21BrO4: C 59.27, H 5.22, found C 59.00, H 5.03. 
4.5. Synthesis of 3a and 3b. 
A CH2Cl2 solution (30 mL) of 1a or 1c (500 mg, 4.93 mmol) and DDQ (1.34 g, 5.91 mmol) was stirred at room 
temperature for 1 h. The medium was next washed three times with water and brine. The organic layer was dryed over 
MgSO4, filtered and evaporated to dryness. Purification by flash chromatography afforded 3a,b.  
4.5.1. 1-Bromo-2-methoxy-5-(3,4,5-trimethoxyphenyl)naphthalene (3a) 
Yield: 33 %. Rf 0.42 (cyclohexane/EtOAc: 7/3). IR (neat) νmax/ cm-1: 3663, 3324, 2974, 2934, 1672, 1659, 1579, 1499, 
1088, 1045, 730, 700. 1H NMR (300 MHz, CDCl3) δ 8.28 (d, J = 8.6 Hz, 1H), 7.92 (d, J = 9.2 Hz, 1H), 7.59 (dd, J = 
8.6, 7.0 Hz, 1H), 7.35 (dd, J = 7.0, 1.1 Hz, 1H), 7.23 (d, J = 9.4 Hz, 1H), 6.66 (s, 2H), 4.03 (s, 3H), 3.95 (s, 3H), 3.87 (s, 
6H). 13C NMR (75 MHz, CDCl3) δ 153.8, 153.1 (2C), 140.7, 137.5, 136.2, 133.6, 128.3, 127.5, 127.3, 126.0, 125.3, 
113.5, 109.1, 107.4 (2C), 61.1, 57.1, 56.3 (2C). MS (APCI, m/z) 403.1 ([M+H]+, 79Br ), 405.1 ([M+H]+, 81Br).. Anal. 
Calcd for C20H19BrO4: C 59.57, H 4.75, found C 59.41, H 4.63. 
4.5.2. 6-Methoxy-1-(3,4,5-trimethoxyphenyl)naphtalene (3b) 
Yield: 99 %. Rf 0.3 (cyclohexane/EtOAc: 8/2). IR (neat) νmax/ cm-1: 2934, 1672, 1579, 1499, 1410, 1374, 1335, 1235, 
1168, 1124, 1031, 1007, 910, 835, 789, 730, 700, 667, 647. 1H NMR (300 MHz, CDCl3) δ 7.86 (d, J = 9.3 Hz, 1H), 
7.75 (d, J = 8.2 Hz, 1H), 7.48 (t, J = 7.5 Hz, 1H), 7.30 (d, J = 7.1 Hz, 1H), 7.21 (d, J = 1.9 Hz, 1H), 7.12 (dd, J = 9.3 
Hz, J = 1.9 Hz, 1H), 6.70 (s, 2H), 3.95 (s, 6H), 3.88 (s, 6H). 13C NMR (75 MHz, CDCl3) δ 157.5, 152.9 (2C), 140.2, 
137.3, 136.5, 135.1, 127.6, 127.1, 126.5, 125.9, 124.5, 118.7, 107.2 (2C), 106.1, 60.9, 56.2 (2C), 55.3.  MS (APCI, m/z) 
325.2 [M + H]+. Anal. Calcd for C20H20O4: C 74.06, H 6.21, found C 73.80, H 6.13. 
4.6. General procedure for the preparation of anilines 1d, 1i, 1l and 3c. 
A solution of 1a, 1b, 1k or 3a (1 mmol), NaN3 (2 mmol), CuI (0.1 mmol), DMEDA (0.15 mmol) and sodium ascorbate 
0.05 mmol) in a mixture of DMSO/H2O: 5/1 was stirred at 60 °C in a sealed tube. After 12 h, the medium was cooled, 
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quenched with NH4Cl and extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over MgSO4, 
filtered and evaporated to dryness. Purification by flash chromatography afforded compounds 1d, 1i, 1l and 3c. 
4.6.1. 2-Methoxy-5-(3,4,5-trimethoxyphenyl)-7,8-dihydronahtalen-1-amine (1d) 
Yield: 59 %. Rf 0.6 (cyclohexane/EtOAc: 5/5). IR (neat) νmax/ cm-1: 3663, 3324, 2974, 1659, 1088, 1045. 1H NMR (300 
MHz, CDCl3) δ 6.52 (d, J = 8.4 Hz, 1H), 6.48 (s, 2H), 6.43 (d, J = 8.4 Hz, 1H), 5.84 (t, J = 4.6 Hz, 1H), 3.81 (s, 3H), 
3.77 (s, 3H), 3.76 (s, 6H), 2.60 (t, J = 7.9 Hz, 2H), 2.34 (m, 2H), NH2 not seen. 13C NMR (75 MHz, CDCl3) δ 152.9 
(2C), 147.2, 140.1, 137.3, 132.7, 128.3, 124.2, 121.2, 116.7, 107.2, 106.2 (2C), 61.0, 56.2 (2C), 55.7, 23.0, 21.7 (1C 
missing). MS (APCI, m/z) 342.2 [M + H]+. Anal. Calcd for C20H23NO4: C 70.36, H 6.79, N 4.10 found C 70.01, H 6.48, 
N 3.98. 
4.6.2. 5-(3,5-Dimethoxyphenyl)-1-amino-2-methoxy-1,2-dihydronaphtalene (1i) 
Yield: 73 %. Rf 0.8 (cyclohexane/EtOAc: 7/3). IR (neat) νmax/ cm-1: 3669, 3324, 2974, 1670, 1088, 1045. 1H NMR (300 
MHz, CDCl3) δ 6.49-6.42 (m, 4H), 6.35 (t, J = 2.3 Hz, 1H), 5.84 (t, J = 4.6 Hz, 1H), 3.75 (s, 3H), 3.72 (m, 2H), 3.69 (s, 
6H), 2.58 (t, J = 7.9 Hz, 2H), 2.32 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 160.5 (2C), 147.2, 143.8, 140.1, 132.7, 128.2, 
124.3, 121.2, 116.8, 107.0 (3C), 99.4, 55.7, 55.5 (2C), 23.0, 21.7. MS (APCI, m/z) 312.9 [M + H]+. Anal. Calcd for 
C19H21NO3: C 73.29, H 6.80, N 4.50 found C 73.04, H 6.62, N 4.40. 
4.6.3. 3-Methoxy-8-(3,4,5-trimethoxyphenyl)-5,6-dihydronaphtalen-2-amine (1l) 
Yield: 72 %. Rf 0.6 (cyclohexane/EtOAc: 5/5). IR (neat) νmax/ cm-1: 2934, 2251, 2157, 1978, 1578, 1508, 1462, 1410, 
1366, 1339, 1285, 1243, 1214, 1158, 1124, 1006, 909, 823, 731. 1H NMR (300 MHz, CDCl3) δ 6.68 (s, 1H), 6.55 (s, 
2H), 6.49 (s, 1H), 5.94 (t, J = 4.6 Hz, 1H), 3.89 (s, 3H), 3.87 (s, 3H), 3.84 (s, 6H), 2.76 (t, J = 7.7 Hz, 2H), 2.35 (m, 
2H), NH2 not seen. 13C NMR (75 MHz, CDCl3) 153.0 (2C), 146.5, 145.9, 139.7, 137.1, 133.4, 128.0, 127.8, 125.2, 
113.6, 110.5, 105.9 (2C), 61.0, 56.3 (2C), 55.8, 28.2, 23.9. MS (APCI, m/z) 342.0 [M + H]+. Anal. Calcd for 
C20H23NO4: C 70.36, H 6.79, N 4.10 found C 69.88, H 6.39, N 3.89. 
4.6.4. 2-Methoxy-5-(3,4,5-trimethoxyphenyl)naphtalen-1-amine (3c) 
Yield: 46 %. Rf 0.33 (cyclohexane/EtOAc: 7/3). IR (neat) νmax/ cm-1: 3663, 3324, 2974, 2934, 1672, 1659, 1579, 1088, 
1045. 1H NMR (300 MHz, CDCl3) δ 7.72 (d, J = 8.5 Hz, 1H), 7.36 (m, 2H), 7.20 (d, J = 7.0 Hz, 1H), 7.12 (d, J = 9.2 
Hz, 1H), 6.62 (s, 2H), 4.27 (br s, 2H), 3.89 (s, 3H), 3.87 (s, 3H), 3.79 (s, 6H). 13C NMR (75 MHz, CDCl3) δ 153.1 (2C), 
142.6, 140.8, 137.2, 137.0, 129.8, 127.7, 124.6 (2C), 124.4, 120.1, 116.9, 113.4, 107.3 (2C), 61.1, 56.7, 56.3 (2C). MS 
(APCI, m/z) 362 [M + Na]+. Anal. Calcd for C20H21NO4: C 70.78, H 6.24, N 4.13, found C 70.55, H 6.15, N 4.01. 
4.7. General procedure for the preparation of naphtols 1e, 1h and 3d. 
A solution of 1a,b, and 3a (1 mmol), KOH (5 mmol), Pd2dba3 (0.1 mmol) and tBuXPhos (0.2 mmol) in a mixture of 
dioxane/H2O: 1/1 was stirred at 90 °C in a sealed tube. After 1 h, the medium was cooled to room temperature, 
quenched with NH4Cl and extracted with EtOAc (3 x 10 mL). The combined organic layers were then dried over 
MgSO4, filtered and evaporated to dryness. Purification by flash chromatography afforded compounds 1e, 1h and 3d. 
4.7.1. 2-Methoxy-5-(3,4,5-trimethoxyphenyl)-7,8-dihydronaphtalen-1-ol (1e) 
Yield: 63 %. Rf 0.52 (cyclohexane/EtOAc: 7/3). IR (neat) νmax/ cm-1: 2941, 2177, 1581, 1489, 1355, 1234, 1126, 905, 
726, 652, 610. 1H NMR (300 MHz, CDCl3) δ 6.63 (d, J = 8.5 Hz, 1H), 6.59 (d, J = 8.5 Hz, 1H), 6.56 (s, 2H), 5.97 (t, J 
= 4.6 Hz, 1H), 5.72 (s, 1H), 3.89 (s, 6H), 3.84 (s, 6H), 2.89 (t, J = 7.9 Hz, 2H), 2.38 (m, 2H). 13C NMR (75 MHz, 
CDCl3) δ 153.0 (2C), 146.0, 142.1, 139.7, 137.0, 129.1, 125.5, 122.4, 117.6, 107.4, 106.1 (2C), 61.1, 56.3 (2C), 56.1, 
23.0, 20.4, (1 C missing). MS (APCI, m/z) 343.2 [M + H]+. Anal. Calcd for C20H22O5: C 70.16, H 6.48, found C 70.00, 
H 6.32. 
4.7.2. 5-(3,5-Dimethoxyphenyl)-2-methoxy-7,8-dihydronaphtalen-1-ol (1h) 
Yield: 62 %. Rf 0.46 (cyclohexane/EtOAc: 7/3). IR (neat) νmax/ cm-1: 2934, 1590, 1489, 1353, 1276, 1204, 1152, 1095, 
1069, 826. 1H NMR (300 MHz, CDCl3) δ 6.60 (s, 1H), 6.58 (d, J = 2.3 Hz, 1H ), 6.50 (d, J = 2.3 Hz, 2H), 6.44 (t, J = 
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2.3 Hz, 1H), 5.98 (t, J = 4.7 Hz, 1H), 5.71 (s, 1H), 3.88 (s, 3H), 3.79 (s, 6H), 2.88 (t, J = 8.0 Hz, 2H), 2.37 (m, 2H). 13C 
NMR (75 MHz, CDCl3) δ 160.6 (2C), 145.9, 143.4, 142.1, 140.0, 129.0, 125.7, 122.4, 117.6, 107.4, 107.0 (2C), 99.5, 
56.1, 55.5 (2C), 23.0, 20.4. MS (APCI, m/z) 313.2 [M + H]+. Anal. Calcd for C19H20O4: C 73.06, H 6.45, found C 
72.99, H 6.39. 
4.7.3. 2-Methoxy-5-(3,4,5-trimethoxyphenyl)naphtalen-1-ol (3d) 
Yield: 82 %. Rf 0.39 (cyclohexane/EtOAc: 7/3). IR (neat) νmax/ cm-1: 2936, 1579, 1500, 1461, 1403, 1340, 1235, 1123, 
1073, 1005, 896, 797, 729. 1H NMR (300 MHz, CDCl3) δ 8.20 (d, J = 7.0 Hz, 1H), 7.53 – 7.44 (m, 2H), 7.31 (dd, J = 
7.0 Hz, J = 1.2 Hz, 1H), 7.22 (d, J = 9.3 Hz, 1H), 6.70 (s, 2H), 4.00 (s, 3H), 3.94 (m, 3H), 3.87 (s, 6H), OH not seen. 
13C NMR (75 MHz, CDCl3) δ 153.0 (2C), 141.2, 139.9, 139.8, 137.2, 136.8, 127.8, 125.2, 125.0, 124.5, 121.0, 118.0, 
113.1, 107.3 (2C), 61.1, 57.2, 56.3 (2C). MS (APCI, m/z) 341 [M + H]+. Anal. Calcd for C20H20O5: C 70.57, H 5.92, 
found C 70.30, H 5.67. 
4.8. General procedure for the synthesis of alkynes 1f, 1g, 3e and 3f. 
A DMF solution of 1a and 3a (1 mmol), alkyne (1.2 mmol), PdCl2(PPh3)2 (0.05 mmol), PPh3 (0.1 mmol), CuI (0.05 
mmol) and Et2NH (2 mmol) was stirred at 120 °C under microwave irradiation. After 25 min, the medium was cooled 
down to room temperature, quenched with NH4Cl and extracted with EtOAc (3 x 10 mL). The combined organic layers 
were then dried over MgSO4, filtered and evaporated to dryness. Purification by flash chromatography afforded 
compounds 1f, 1g, 3e and 3f. 
4.8.1. 4-(2-Methoxy-5-(3,4,5-trimethoxyphenyl)-7,8-dihydronaphtalen-1-ul)but-3-yn-1-ol (1f) 
Yield: 41 %. Rf 0.6 (cyclohexane/EtOAc: 4/6). IR (neat) νmax/ cm-1: 2922, 1590, 1489, 1413, 1353, 1267, 1128, 905, 
812, 738. 1H NMR (300 MHz, CDCl3) δ 6.97 (d, J = 8.6 Hz, 1H), 6.63 (d, J = 8.6 Hz, 1H), 6.53 (s, 2H), 5.98 (t, J = 4.5 
Hz, 1H), 3.89 (s, 3H), 3.87 (s, 3H), 3.84 (m, 8H), 3.02 (t, J = 7.8 Hz, 2H), 2.81 (t, J = 6.0 Hz, 2H), 2.39 (m, 2H), OH 
not seen. 13C NMR (75 MHz, CDCl3) 159.3 (2C), 152.9, 140.6, 139.2, 137.1, 136.5, 128.2, 126.2, 125.3, 111.2 (2C), 
107.3, 105.7, 95.1, 77.7, 61.1, 60.9, 56.1, 55.8 (2C), 26.3, 24.4, 23.0. MS (APCI, m/z) 395.6 [M + H]+. Anal. Calcd for 
C24H26O5: C 73.08, H 6.64, found C 72.79, H 6.38. 
4.8.2. 3-(2-Methoxy-5-(3,4,5-trimethoxyphenyl)-7,8-dihydronaphtalen-1-yl)prop-2-yn-1-ol (1g) 
Yield: 25 %. Rf 0.57 (cyclohexane/EtOAc: 4/6). IR (neat) νmax/ cm-1: 2922, 1590, 1489, 1413, 1353, 1267, 1128, 905, 
805, 726, 649. 1H NMR (300 MHz, CDCl3) δ 7.00 (d, J = 8.6 Hz, 1H), 6.64 (d, J = 8.6 Hz, 1H), 6.53 (s, 2H), 5.99 (t, J 
= 4.3 Hz, 1H), 4.61 (s, 2H), 3.89 (s, 3H), 3.87 (s, 3H), 3.84 (s, 6H), 3.04 (t, J = 7.7 Hz, 2H), 2.38 – 2.19 (m, 2H). OH 
not seen. 13C NMR (75 MHz, CDCl3) 159.3, 152.9 (2C), 141.2, 139.1, 137.1, 136.5, 127.9, 126.7, 125.4, 110.4, 107.4, 
105.8 (2C), 95.8, 80.2, 60.9, 56.1 (2C), 55.8, 51.9, 26.2, 22.9. MS (APCI, m/z) 381.8 [M + H]+. Anal. Calcd for 
C23H24O5: C 72.61, H 6.36, found C 72.56, H 6.12. 
4.8.3. 3-(2-Methoxy-5-(3,4,5-trimethoxyphenyl)naphtalen-1-yl)but-3-yn-1-ol (3e) 
Yield: 52 %. Rf 0.22 (cyclohexane/EtOAc: 6/4). IR (neat) νmax/ cm-1: 2934, 1580, 1501, 1463, 1409, 1320, 1266, 1236, 
1183, 1124, 1060, 1005, 910, 850, 730, 686. 1H NMR (300 MHz, CDCl3) δ 8.27 (d, J = 8.4 Hz, 1H), 7.90 (d, J = 9.4 
Hz, 1H), 7.60 – 7.48 (m, 1H), 7.31 (d, J = 6.8 Hz, 1H), 7.19 (d, J = 9.4 Hz, 1H), 6.66 (s, 2H), 4.01 (s, 3H), 3.98 – 3.89 
(m, 5H), 3.87 (s, 6H), 2.92 (t, J = 6.1 Hz, 2H), OH not seen. 13C NMR (75 MHz, CDCl3) 158.7, 152.9 (2C), 140.5, 
137.3, 136.2, 134.9, 127.9, 126.8, 126.7, 124.9 (2C), 112.4, 107.3 (2C), 106.5, 96.4, 77.3, 61.2, 60.9, 56.5, 56.2 (2C), 
24.6. MS (APCI, m/z) 393.3 [M + H]+. Anal. Calcd for C24H24O5: C 73.45, H 6.16, found C 73.34, H 6.02. 
4.8.4. 3-(2-Methoxy-5-(3,4,5-trimethoxyphenyl)naphthalen-1-yl)prop-2-yn-1-ol (3f) 
Yield: 49 %. Rf 0.14 (cyclohexane/EtOAc: 2/8). IR (neat) νmax/ cm-1: 2922, 1501, 1463, 1413, 1267, 1128, 905, 805, 
726, 649. 1H NMR (300 MHz, CDCl3) δ 8.35 (d, J = 8.4 Hz, 1H), 8.00 (d, J = 9.4 Hz, 1H), 7.63 (dd, J = 8.4 Hz, J = 7.0 
Hz, 1H), 7.39 (d, J = 7.0 Hz, 1H), 7.26 (d, J = 9.5 Hz, 1H), 6.73 (s, 2H), 4.80 (s, 2H), 4.08 (s, 3H), 4.01 (s, 3H), 3.94 (s, 
6H), OH not seen. 13C NMR (75 MHz, CDCl3) 158.1 (2C), 152.1, 139.8, 135.3, 134.2, 127.9, 126.1, 125.9, 124.2, 
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124.0, 115.5, 106.3 (2C), 96.2, 79.3, 60.2, 55.6, 55.4 (2C), 51.3, two C missing. MS (APCI, m/z) 379.5 [M + H]+. Anal. 
Calcd for C23H22O5: C 73.00, H 5.86, found C 72.87, H 5.76. 
4.9. General procedure for the synthesis of compounds 1j and 3g. 
A NMP solution of 1a or 3a (1 mmol), methyl acrylate (10 mmol), PEPPSI (0.05 mmol) and K2CO3 (2 mmol) was 
stirred at 140 °C in a sealed tube. After 1 h, the medium was cooled down to room temperature, quenched with NH4Cl 
and extracted with EtOAc (3 x 10 mL). The combined organic layers were then dried over MgSO4, filtered, and the 
solvent was then removed. Purification by flash chromatography afforded compounds 1j and 3g. 
4.9.1. Methyl-3-(2-methoxy-5-(3,4,5-trimethoxyphenyl)-7,8-dihydronaphtalen-1-yl)acrylate (1j) 
Yield: 35 %. 0.41 Rf (cyclohexane/EtOAc: 7/3). IR (neat) νmax/ cm-1: 2945, 2500, 1714, 1579, 1504, 1463, 1412, 1352, 
1252, 1169, 1124, 1007, 911. 1H NMR (300 MHz, CDCl3) δ 7.99 (d, J = 16.2 Hz, 1H), 7.05 (d, J = 8.6 Hz, 1H), 6.69 (d, 
J = 8.6 Hz, 1H), 6.53 (s, 2H), 6.45 (d, J = 16.2 Hz, 1H), 6.01 (t, J = 4.1 Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.83 (s, 6H), 
3.81 (s, 3H), 2.96 (t, J = 7.7 Hz, 2H), 2.33 (m, 2H). 13C NMR (75 MHz, CDCl3) 167.9, 157.7, 153.0 (2C), 139.6, 139.1, 
138.1, 137.1, 136.7, 128.6, 127.9, 125.1, 123.4, 121.8, 107.8, 105.8 (2C), 60.9, 56.1 (2C), 55.5, 51.6, 25.3, 23.2. MS 
(APCI, m/z) 411.8 [M + H]+. Anal. Calcd for C24H26O6: C 70.23, H 6.38, found C 70.11, H 6.31. 
4.9.2. Methyl-3-(2-methoxy-5-(3,4,5-trimethoxyphenyl)naphtalen-1-yl)acrylate (3g) 
Yield: 22 %. Rf 0.44 (cyclohexane/EtOAc: 7/3). IR (neat) νmax/ cm-1: 3976, 3412, 2939, 2185, 1713, 1579, 1503, 1464, 
1414, 1278, 1171, 1153, 1126, 1063, 1008, 806. 1H NMR (300 MHz, CDCl3) δ 8.38 (d, J = 16.2 Hz, 1H), 8.20 (d, J = 
8.9 Hz, 1H), 7.96 (d, J = 8.9 Hz, 1H), 7.54 (t, J = 7.2 Hz, 1H), 7.33 (d, J = 7.2 Hz, 1H), 7.24-7.10 (m, 1H), 6.77 (d, J = 
16.2 Hz, 1H), 6.66 (s, 2H), 3.99 (s, 3H), 3.94 (s, 3H), 3.87 (s, 9H). 13C NMR (75 MHz, CDCl3) 168.4, 156.5, 153.1 
(2C), 141.1, 138.3, 137.4, 136.5, 133.3, 129.9, 127.3, 126.9, 124.9, 123.4, 123.1, 116.9, 112.7, 107.3 (2C), 77.2, 61.1, 
56.3 (2C), 51.8. MS (APCI, m/z) 409.7 [M + H]+. Anal. Calcd for C24H24O6: C 70.57, H 5.92, found C 70.21, H 5.68. 
4.10. General procedure for catalytic hydrogenation. 
A solution of suitable precursor (50 mg) and Pd/C (5 mg) in MeOH (8 mL) was stirred under a H2 atmosphere at room 
temperature. After 4 h, the medium filtered over a pad of Celite and the solvent was removed in vacuo. Purification by 
flash chromatography afforded compounds 2a-e and 3h. 
4.10.1. 6-Methoxy-1-(3,4,5-trimethoxyphenyl)-1,2,3,4-tetrahydronaphthalene (2a) 
Yield: 76 %. Rf 0.6 (cyclohexane/EtOAc: 8/2). IR (neat) νmax/ cm-1: 2931, 1589, 1500, 1462, 1417, 1328, 1232, 1124, 
1038, 1007, 908, 826, 727, 647. 1H NMR (300 MHz, CDCl3) δ 6.80 (d, J = 8.3 Hz, 1H), 6.68 – 6.58 (m, 2H), 6.31 (s, 
2H), 4.01 – 3.94 (m, 1H), 3.83 (s, 3H), 3.78 (s, 9H), 2.93 – 2.79 (m, 2H), 2.19 – 2.07 (m, 1H), 1.95 – 1.84 (m, 2H), 1.84 
– 1.68 (m, 1H). 13C NMR (75 MHz, CDCl3) 157.7, 153.0 (2C), 143.5, 138.7, 136.2, 131.6, 131.2, 113.3, 112.1, 105.8 
(2C), 60.9, 56.2 (2C), 55.3, 45.6, 33.6, 30.2, 21.5. MS (APCI, m/z) 329.1 [M + H]+. Anal. Calcd for C20H24O4: C 73.15, 
H 7.37, found C 72.89, H 7.13. 
4.10.2. 2-Methoxy-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydronaphtalen-1-amine (2b) 
Yield: 47 %. Rf 0.49 (cyclohexane/EtOAc: 6/4). IR (neat) νmax/ cm-1: 2933, 1600, 1492, 1458, 1233, 1127. 1H NMR 
(400 MHz, CDCl3) δ 6.60 (d, J = 8.2 Hz, 1H), 6.31 (d, J = 8.1 Hz, 1H), 6.32 (s, 2H), 3.99 (m, 1H), 3.83 (s, 3H), 3.83 (s, 
3H), 3.78 (s, 6H), 2.59 (m, 2H), 2.07 (m, 1H), 1.96 (m, 1H), 1.83-1.81 (m, 2H), NH2 not seen. The presence of an 
impurity complicates the NMR spectra and despite our best efforts, we were not able to obtain 2b with a satisfactory 
elemental analysis 13C NMR (100 MHz, CDCl3) 153.0 (2C), 145.1, 143.5, 136.2, 133.2, 132.3, 122.8, 119.6, 108.2, 
106.0 (2C), 61.0, 56.2 (2C), 55.7, 46.0, 32.7, 24.7, 20.8. MS (APCI, m/z) 344.2 [M + H]+. 
4.10.3. 2-Methoxy-5-(3,4,5-trimethoxyphenyl)-5,6,7,7-tetrahydronaphtalen-1-ol (2c) 
Yield: 50 %. Rf 0.66 (cyclohexane/EtOAc: 7/3). IR (neat) νmax/ cm-1: 3518, 2930, 2004, 1589, 1492, 1459, 1280, 1234, 
1126, 907, 731, 624. 1H NMR (300 MHz, CDCl3) δ 6.63 (d, J = 8.5 Hz, 1H), 6.39 (d, J = 8.5 Hz, 1H), 6.32 (s, 2H), 5.69 
(br s, 1H), 3.96 (m, 1H), 3.86 (s, 3H), 3.84 (s, 3H), 3.79 (s, 6H), 2.96 – 2.65 (m, 2H), 2.17 – 1.73 (m, 4H). 13C NMR (75 
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MHz, CDCl3) 153.0 (2C), 144.0, 143.4, 142.6, 133.0, 124.3, 120.9, 108.2, 105.9 (2C), 61.0, 56.2 (2C), 56.1, 45.9, 33.0, 
23.3, 20.7 (one C missing). MS (APCI, m/z) 345.2 [M + H]+. Anal. Calcd for C20H24O5: C 69.75, H 7.02, found C 
69.51, H 6.85. 
4.10.4. 4-(2-Methoxy-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydronaphtalen-1-yl)butan-1-ol (2d) 
Yield: 34 %. Rf 0.31 (cyclohexane/EtOAc: 6/4). IR (neat) νmax/ cm-1: 2004, 1589, 1492, 1459, 1280, 1234, 1154, 1126, 
1064, 1007, 806, 730, 613. 1H NMR (300 MHz, CDCl3) δ 6.71 (d, J = 8.4 Hz, 1H), 6.63 (d, J = 8.4 Hz, 1H), 6.31 (s, 
2H), 4.04 – 3.94 (m, 1H), 3.84 (s, 3H), 3.78 (s, 9H), 3.71 (t, J = 6.6 Hz, 1H), 2.82 (t, J = 6.6 Hz, 2H), 2.68 (dd, J =12.7 
Hz, J =6.4 Hz, 2H), 2.16 – 1.48 (m, 10H). 13C NMR (75 MHz, CDCl3) 155.6, 153.1 (2C), 143.6, 136.5, 136.3, 131.9, 
128.5, 128.4, 108.4, 106.1 (2C), 63.0, 60.9, 56.2 (2C), 55.6, 46.4, 33.0, 32.8, 26.8, 25.4, 25.4, 21.5. MS (APCI, m/z) 
423.3 [M + Na]+. Anal. Calcd for C24H32O5: C 71.97, H 8.05, found C 71.59, H 7.83. 
4.10.5. 1-(3,5-Dimethoxyphenyl)-6-methoxy-1,2,3,4-tetrahydronaphtalene (2e) 
Yield: 72 %. Rf 0.25 (cyclohexane/EtOAc: 8/2). IR (neat) νmax/ cm-1: 2939, 2835, 2049, 2000, 1595, 1501, 1462, 1427, 
1323, 1254, 1204, 1154, 1064, 832, 697. 1H NMR (300 MHz, CDCl3) δ 6.80 (d, J = 8.3 Hz, 1H), 6.68 – 6.54 (m, 2H), 
6.31 (t, J = 2.3 Hz, 1H), 6.26 (d, J = 2.2 Hz, 2H), 3.99 (t, J = 6.7 Hz, 1H), 3.78 (s, 3H), 3.75 (s, 6H), 2.96 – 2.71 (m, 
2H), 2.20 – 2.03 (m, 1H), 1.95 – 1.79 (m, 2H), 1.79 – 1.65 (m, 1H). 13C NMR (75 MHz, CDCl3) 160.5 (2C), 157.6, 
150.2, 138.6, 131.4, 131.3, 113.2, 112.1, 107.1 (2C), 97.6, 55.2 (2C), 55.2, 45.2, 33.1, 30.1, 21.0. MS (APCI, m/z) 
299.1 [M + H]+. Anal. Calcd for C19H22O3: C 76.48, H 7.43, found C 76.09, H 7.23. 
4.10.6. 3-(2-Methoxy-5-(3,4,5-trimethoxyphenyl)naphtalen-1-yl)propan-1-ol (3h) 
Yield: 82 %. Rf 0.2 (cyclohexane/EtOAc: 3/7). IR (neat) νmax/ cm-1: 2932, 2035, 1582, 1501, 1462,  1415, 1332, 1257, 
1126, 1040, 1007, 806, 730, 613. 1H NMR (300 MHz, CDCl3) δ 8.01 (d, J = 8.6 Hz, 1H), 7.85 (d, J = 9.4 Hz, 1H), 7.53 
(dd, J = 8.6 Hz, J = 7.0 Hz, 1H), 7.31 (d, J = 6.9 Hz, 1H), 7.24 (d, J = 10.4 Hz, 1H), 6.68 (s, 2H), 3.98 (s, 3H), 3.95 (s, 
3H), 3.87 (s, 6H), 3.59 (t, J = 5.8 Hz, 2H), 3.27 (t, J = 7.0 Hz, 2H), 1.98 (m, 2H), OH not seen. 13C NMR (75 MHz, 
CDCl3) 154.2, 152.9 (2C), 140.9, 136.7, 133.3, 127.7, 126.2, 125.9, 124.3, 122.8, 122.5 (2C), 112.9, 107.2 (2C), 61.6, 
60.9, 56.7, 56.2 (2C), 32.2, 20.6. MS (APCI, m/z) 383.8 [M + H]+. Anal. Calcd for C23H26O5: C 72.23, H 6.85, found C 
72.00, H 6.58. 
4.11. Biolology 
4.11.1. Cell Culture and Proliferation Assay. 
Cancer cell lines were obtained from the American type Culture Collection (Rockville, MD) and were cultured 
according to the supplier’s instructions. Briefly MDA-MB-231 and H1299 cells were grown in Dulbecco minimal 
essential medium (DMEM) containing 4.5 g/L glucose supplemented with 10% FCS and 1% glutamine. Human K562 
leukemia and HCT116 colorectal carcinoma cells were grown in RPMI 1640 containing 10% FCS and 1% glutamine. 
Cell lines were maintained at 37 °C in a humidified atmosphere containing 5% CO2. Cell viability was assessed using 
Promega CellTiter-Blue TM reagent according to the manufacturer’s instructions. Cells were seeded in 96-well plates 
(5 × 103 cells/well) containing 50 μL growth medium. After 24 h of culture, the cells were supplemented with 50 μL of 
the tested compound dissolved in DMSO (less than 0.1% in each preparation). After 72 h of incubation, 20 μL of 
resazurin was added for 2 h before recording fluorescence (λex = 560 nm, λem = 590 nm) using a Victor microtiter 
plate fluorimeter (Perkin-Elmer,USA). The GI50 corresponds to the concentration of the tested compound that caused a 
decrease of 50% in fluorescence of drug treated cells compared with untreated cells. Experiments were performed in 
triplicate. The GI50 values for all compounds were compared to the GI50 of CA4, isoCA-4 and isoerianin and measured 
the same day under the same conditions. 
4.11.2. Tubulin Binding Assay 
Sheep brain tubulin was purified according to the method of Shelanski[41] by two cycles of assembly-disassembly and 
then dissolved in the assembly buffer containing 0.1 M MES, 0.5 mM MgCl2, 1 mM EGTA, and 1 mM GTP, pH 6.6 
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(the concentration of tubulin was about 2-3 mg/mL). Tubulin assembly was monitored by fluorescence according to 
reported procedure[50] using DAPI as fluorescent molecule. Assays were realized on 96-well plates prepared with 
Biomek NKMC and Biomek 3000 from Beckman Coulter and read at 37°C on Wallac Victor fluorimeter from 
Perkin Elmer. The IC50 value of each compound was determined as the concentration which decreased the maximum 
assembly rate of tubulin by 50% compared to the rate in the absence of compound. The IC50 values for all compounds 
were compared to the IC50 of CA4, isoCA-4 and isoerianin and measured the same day under the same conditions. 
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Legends to Figures, Schemes and Tables 
 
Figure 1 Representative tubulin binding agents and general structure of the synthesized analogues 1-3. 
 
Scheme 1 Synthesis of compounds 1-3. 
 
Scheme 2 Synthesis of compounds 1k,l. 
 
Table 1 Cytotoxicity of compounds 1-3 against HCT 116 cells.a 
 
Table 2. Cytotoxicities of selected compounds against different human cancer cell lines and inhibition of tubulin 
polymerization (ITP). 
Table 3. Evaluation of G2/M arrest in MDA-MB231, K562, HCT116 and H1299 cells exposed to 2c, 1e and 3d. 
Figure 2. Docked pose of 2c, 1e and 3c overlayed with isoCA-4 and isoerianin in the tubulin binding site. 
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Cytotoxicity 
GI50b [nM] 
70 ± 6 20 ± 1.5 1700 ± 100 250 ± 28 
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3a 3b 3c 3d 
Cytotoxicity 
GI50b [nM] 
800 ± 70 800 ± 60 55 ± 6 250 ± 30 
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 3e 3f 3g 3h 
Cytotoxicity 
GI50b [nM] 
5500 ± 500 Ncc Ncc Ncc 
 
MeO
MeO
OMe
OMe
OH
  
 
 
 isoCA-4 isoerianin CA-4  
 
3 ± 0.2d 28 ± 2 2 ± 0.1d  
a HCT116: human colon carcinoma cells. b GI50 is the concentration of compound needed to reduce cell growth by 50% following 72 
h cell treatment with the tested drug (average of three experiments). c GI50 value not calculated owing to the low activity of the 
compound. d The GI50 values for isoCA-4, isoerianin and CA-4 were determined in this study. 
 
<Table 1> 
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Compound 
GI50a [nM] Inhibition of tubulin 
polymerization  
IC50b [M] 
Non-small lung human carcinoma 
(H1299) 
Human breast cancer 
(MDA-MB231) 
Chronic mylogenous 
leukemia (K562) 
1d 30 ± 2 85 ± 5 180 ± 14 2.1 ± 0.2 
1e 32 ± 2.5 20 ± 1.5 15 ± 0.8 1.9 ± 0.2 
1h 33 ± 2 20 ± 1 20 ± 1.5 2.0 ± 0.2 
1i 32 ± 2 70 ± 6 200± 12 3.1 ± 0.5 
2a 80 ± 7 100 ± 7 150± 10 c 
2b 45 ± 3 70 ± 3 110± 9 c 
2c 30 ± 2.5 30 ± 2 55± 3 3.0 ± 0.3 
3c 90 ± 7 60 ± 4 85± 5 2.0 ± 0.3 
3d 310 ± 25 500 ± 35 380± 25 6.9 ± 0.8 
isoCA-4 3 ± 0.4 4 ± .5 5± 4 2.2 ± 0.2d 
isoerianin 38 ± 3 40 ± 5 20± 1.5 3.2 ± 0.3d 
CA-4 5 ± 0.4 3 ± 0.3 4± 0.3 1.0 ± 0.2d 
a GI50 is the concentration of compound needed to reduce cell growth by 50% following 72 h cell treatment with the tested drug 
(average of three experiments). b ITP, inhibition of tubulin polymerization; IC50 is the concentration of compound required to inhibit 
50% of the rate of microtubule assembly (average of three experiments). c IC50 value not calculated owing to the low activity of the 
compound. d The GI50 and IC50 values for isoCA-4, isoerianin and CA-4 were determined in this study. 
 
<Table 2> 
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Untreated cells 2c: 5.10-9 M 1e: 10-8 M 3d: 5.10-7 M 
 
   
MDA-MB231 cells 
    
K562 cells 
 
 
 
 
HCT116 cells 
    
H1299 cells 
 
<Table 3> 
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Superimposition of 2c and isoCA-4 (blue) Superimposition of 1e and isoCA-4 (blue) 
  
Superimposition of 3d and isoerianin (green) Superimposition of 1e, 2c and 3d 
 
<Figure 2> 
